BONOQ URO 400 mg tabletti, kalvopäällysteinen Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

bonoq uro 400 mg tabletti, kalvopäällysteinen

grünenthal gmbh - gatifloxacini sesquihydricum - tabletti, kalvopäällysteinen - 400 mg - gatifloksasiini

CRISPIN URO 200 mg tabletti, kalvopäällysteinen Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

crispin uro 200 mg tabletti, kalvopäällysteinen

grünenthal gmbh - gatifloxacini sesquihydricum - tabletti, kalvopäällysteinen - 200 mg - gatifloksasiini

CRISPIN URO 400 mg tabletti, kalvopäällysteinen Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

crispin uro 400 mg tabletti, kalvopäällysteinen

grünenthal gmbh - gatifloxacini sesquihydricum - tabletti, kalvopäällysteinen - 400 mg - gatifloksasiini

ISOTRETINOIN ORIFARM 10 mg kapseli, pehmeä Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

isotretinoin orifarm 10 mg kapseli, pehmeä

orifarm generics a/s orifarm generics a/s - isotretinoinum - kapseli, pehmeä - 10 mg - isotretinoiini

NAPROXEN ORION 25 mg/ml oraalisuspensio Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

naproxen orion 25 mg/ml oraalisuspensio

orion corporation - naproxenum - oraalisuspensio - 25 mg/ml - naprokseeni

Venclyxto Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

venclyxto

abbvie deutschland gmbh co. kg - venetoclax - leukemia, lymfosyyttinen, krooninen, b-solu - antineoplastiset aineet - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.

Heplisav B Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

heplisav b

dynavax gmbh - hepatiitti b-pinta-antigeeni - b-hepatiitti - rokotteet - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

PreHevbri Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

prehevbri

vbi vaccines b.v. - hepatiitti b-pinta-antigeeni - b-hepatiitti - rokotteet - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.